# A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

> **NCT04580121** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 59 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** RO7283420
- **DRUG:** RO7283420
- **DRUG:** Tocilizumab
- **DRUG:** Dasatinib
- **DRUG:** Dexamethasone
- **DRUG:** Paracetamol/acetaminophen
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT04580121
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2023-08-09
- **Final completion:** 2023-08-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04580121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04580121, "A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04580121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*